DermTech (BMV:DMTK *) - Aktienkurs, Nachrichten und Analyse

DMTK * Aktienübersicht

A molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States.

Über das Unternehmen

DMTK * grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 29.43%

Risikoanalyse

Aktien sind hochgradig illiquide

Hat keine nennenswerte Marktkapitalisierung (MX$52M)

Signifikante Insiderverkäufe in den letzten 3 Monaten

Die Aktionäre wurden im vergangenen Jahr verwässert

+ 1 mehr Risiko

DermTech, Inc. Wettbewerber

Pacific Edge

NZSE:PEB

NZ$71.4m

Actinogen Medical

ASX:ACW

AU$85.8m

LAVA Therapeutics

NasdaqGS:LVTX

US$51.8m

Aadi Bioscience

NasdaqCM:AADI

US$40.0m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für DermTech
Historische Aktienkurse
Aktueller Aktienkurs	US$55.65
52-Wochen-Hoch	US$55.65
52-Wochen-Tief	US$55.65
Beta	2.69
11 Monat Veränderung	0%
3 Monate Veränderung	n/a
1 Jahr Veränderung	n/a
33 Jahre Veränderung	n/a
5 Jahre Veränderung	n/a
Veränderung seit IPO	-96.59%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	DMTK *	MX Biotechs	MX Markt
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendite im Vergleich zur Industrie: Unzureichende Daten, um festzustellen, wie DMTK * im Vergleich zur Branche MX Biotechs abschneidet.

Rendite vs. Markt: Unzureichende Daten, um festzustellen, wie DMTK * im Vergleich zum MX Markt abgeschnitten hat.

Preisvolatilität

Is DMTK *'s price volatile compared to industry and market?
DMTK * volatility
DMTK * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiler Aktienkurs: DMTK * hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von DMTK * im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
n/a	279	Bret Christensen	www.dermtech.com

DermTech, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von DermTech im Vergleich zum Marktanteil des Unternehmens?
DMTK * grundlegende Statistiken
Marktanteil	Mex$943.27m
Gewinn(TTM)	-Mex$2.18b
Umsatz(TTM)	Mex$255.05m

3.7x

Kurs-Umsatz-Verhältnis

-0.4x

Kurs-Gewinn-Verhältnis

Ist DMTK * zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
DMTK * Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$14.02m
Kosten der Einnahmen	US$14.84m
Bruttogewinn	-US$813.00k
Sonstige Ausgaben	US$118.82m
Umsatz	-US$119.63m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-3.55
Bruttomarge	-5.80%
Nettogewinnspanne	-853.02%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich DMTK * auf lange Sicht entwickelt?

Historische Performance und Vergleiche

DMTK * Aktienübersicht

Belohnungen

Risikoanalyse

DermTech, Inc. Wettbewerber

NZSE:PEB

NZ$71.4m

ASX:ACW

AU$85.8m

NasdaqGS:LVTX

US$51.8m

NasdaqCM:AADI

US$40.0m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Motion for Joint Administration Approved for DermTech, Inc.

DermTech, Inc. Filed for Bankruptcy

Kilroy Realty, L.P. Files a Complaint Against DermTech, Inc. for $661,706 in Unpaid Rent

DermTech Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Minimum Bid Price Requirement

DermTech, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

Recent updates

Motion for Joint Administration Approved for DermTech, Inc.

DermTech, Inc. Filed for Bankruptcy

Kilroy Realty, L.P. Files a Complaint Against DermTech, Inc. for $661,706 in Unpaid Rent

DermTech Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Minimum Bid Price Requirement

DermTech, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test (Dmt) Across All Skin Types

DermTech, Inc. Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-On Assay

Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test (Dmt)

Pomerantz LLP Announces the Filing of A Class Action Against DermTech, Inc. and Certain Officers

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against DermTech, Inc

DermTech, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Dermtech Appoints Mark Aguillard as Chief Commercial Officer

DermTech, Inc. to Report Q2, 2023 Results on Aug 03, 2023

New major risk - Financial position

DermTech, Inc. Announces the Todd Wood’s Last Day of Employment as Chief Commercial Officer Will Be July 3, 2023

DermTech, Inc. Announces ECRI Complete Its Evaluation of the Pigmented Lesion Assay

DermTech, Inc. Announces Change of CEO

DermTech, Inc. to Report Q4, 2022 Results on Mar 02, 2023

DermTech, Inc. Announces the Foundational Assay of Its DermTech Melanoma Test Is Recommended for Coverage by TRICARE

DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its Dermtech Melanoma Test (Dmt)

DermTech, Inc. Announces Board Committee Appointments

DermTech, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Chief Operating Officer recently sold Mex$292k worth of stock

High number of new directors

Second quarter 2022 earnings released: US$0.99 loss per share (vs US$0.59 loss in 2Q 2021)

Dermtech, Inc. Provides Revenue Guidance for the Full Year 2022

DermTech, Inc. Appoints Chief Compliance Officer and SVP of Research and Development

DermTech, Inc. to Report Q2, 2022 Results on Aug 08, 2022

High number of new and inexperienced directors

Dermtech Announces New Board Appointment

High number of new and inexperienced directors

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Dynamic Index

DermTech, Inc. Presents New Research Differentiating Atopic Dermatitis and Psoriasis At the Society for Investigative Dermatology's Annual Meeting

DermTech, Inc. Affirms Revenue Guidance for the Full-Year 2022

DermTech, Inc., Annual General Meeting, May 26, 2022

DermTech, Inc. announced delayed annual 10-K filing

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

DermTech, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

High number of new and inexperienced directors

DermTech, Inc. to Report Q4, 2021 Results on Mar 01, 2022

High number of new and inexperienced directors

President recently sold Mex$687k worth of stock

Chief Operating Officer recently sold Mex$1.3m worth of stock

High number of new and inexperienced directors

DermTech Unveils DermTech Stratum

Third quarter 2021 earnings released: US$0.68 loss per share (vs US$0.50 loss in 3Q 2020)

High number of new and inexperienced directors

CFO, Treasurer & Secretary recently sold Mex$3.1m worth of stock

Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.58 loss in 2Q 2020)

High number of new and inexperienced directors

CFO, Treasurer & Secretary recently sold Mex$2.5m worth of stock

President recently sold Mex$7.6m worth of stock

Dermtech, Inc. Provides Earnings Results for the Second Quarter of 2021

DermTech, Inc. Provides No Financial Guidance for the Fiscal Year 2021

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

DermTech, Inc.'s Grundlagenzusammenfassung

Erträge & Einnahmen